Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology firm, will participate in the Canaccord Genuity 41st Annual Growth Conference from August 10-12, 2021. CEO Brian Sullivan will engage in a virtual fireside chat on August 12, 2021, at 8:30 a.m. ET. Interested parties can access the live webcast here or via the company’s Investors page. Celcuity focuses on enhancing cancer patient outcomes through its CELsignia diagnostic platform and related therapeutic strategies.

MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present in a virtual fireside chat at 8:30 a.m. ET on Thursday, August 12, 2021.

A live webcast of the fireside chat will be available at: https://wsw.com/webcast/canaccord60/celc/2404732. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://celcuity.com/investors/events-webcasts/ with a replay available shortly after the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated companion diagnostic and therapeutic strategy. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Its therapeutic efforts are focused on in-licensing and developing molecularly targeted therapies that address the same cancer driver its companion diagnostics can identify. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

Westwicke ICR
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/658530/Celcuity-to-Participate-in-the-Canaccord-Genuity-41st-Annual-Growth-Conference

FAQ

When is Celcuity's presentation at the Canaccord Genuity Growth Conference?

Celcuity's presentation is scheduled for August 12, 2021, at 8:30 a.m. ET.

How can I watch Celcuity's fireside chat during the conference?

You can watch the fireside chat live at this link or on the company's Investors section.

What does Celcuity Inc. specialize in?

Celcuity specializes in developing companion diagnostics and targeted therapies for cancer patients.

What is the CELsignia platform at Celcuity?

CELsignia is a companion diagnostic platform that analyzes live tumor cells to identify cancer patients who may benefit from existing targeted therapies.

Where is Celcuity located?

Celcuity is headquartered in Minneapolis, MN.